NCT01794793 / 2013-000267-84: Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies |
|
|
| Completed | 4 | 337 | Europe, Canada, Japan, US, RoW | Pasireotide, SOM230; Signifor, Cabergoline, dostinex, Pasireotide LAR | RECORDATI GROUP | Cushing's Disease, Acromegaly, Neuroendocrine Tumors, Pituitary Tumors, Ectopic ACTH Secreting (EAS) Tumors, Dumping Syndrome, Prostate Cancer, Melanoma Negative for bRAF, Melanoma Negative for nRAS | 07/23 | 07/23 | | |
ACTRN12615001328561: Phase II study evaluating the efficacy of Pasireotide long-acting release (LAR; SOM230) dose escalation in patients with refractory non-functional gastroenteropancreatic neuroendocrine tumors (GEP NETs). |
|
|
| Not yet recruiting | 2 | 30 | | | Peter MacCallum Cancer Centre, Novartis Pty Ltd | Gastro-entero-pancreatic neuroendocrine tumours | | | | |
2010-018795-24: Evaluation of the effect of pasireotide LAR administration in the lymphocele prevention after axillary node dissection for breast cancer |
|
|
| Ongoing | 2 | 90 | Europe | PASIREOTIDE LAR, SOM 230 C, | Alliance pour la recherche en cancérologie | BREAST CANCER | | | | |
NCT01253161: Study of Pasireotide Long Acting Release (LAR) in Patients With Metastatic Neuroendocrine Tumors (NETs) |
|
|
| Completed | 2 | 29 | US | Pasireotide Long Acting Release (LAR), SOM 230 | H. Lee Moffitt Cancer Center and Research Institute, Novartis Pharmaceuticals, RECORDATI GROUP | Neuroendocrine Tumors, Carcinoid Tumors | 10/21 | 03/23 | | |
